3. (Amended) The method of claim 1, wherein IFN_τ is orally-administered at a dosage of greater than about $1x10^6$ units per day.

A1 cancelled

4. (Amended) The method of claim 1, wherein the bovine IFN_τ has an amino acid sequence homology of at least about 80% with an ovine IFN_τ ($OvIFN_\tau$) amino acid sequence.

5. (Amended) The method of claim 1, wherein said bovine IFN_τ has a sequence homology of at least about 80% with an ovine IFN_τ sequence represented as SEQ ID NO:2.

A2

9. (Amended) The method of claim 20, wherein said mammal is a dog.

20. (New) The method of claim 1, wherein the mammal is a domesticated animal.

A3

21. (New) In a method of treating a condition associated with cellular proliferation in a mammal responsive to treatment by ovine interferon-tau (IFN_τ), an improvement comprising orally administering a therapeutically-effective amount of bovine IFN_τ through oral ingestion.

22. (New) The method of claim 21, wherein IFN_τ is orally-administered at a dosage of greater than about $1x10^5$ units per day.

23. (New) The method of claim 21, wherein IFN_τ is orally-administered at a dosage of greater than about $1x10^6$ units per day.

24. (New) The method of claim 21, wherein the bovine IFN_τ has an amino acid sequence homology of at least about 80% with an

ovine IFN_τ ($OvIFN_\tau$) amino acid sequence.

25. (New) The method of claim 21, wherein said bovine IFN_τ has a sequence homology of at least about 80% with an ovine IFN_τ sequence represented as SEQ ID NO:2.

26. (New) The method of claim 21, wherein said mammal is a human.

A3 cont'd

27. (New) The method of claim 21, wherein the mammal is a domesticated animal.

28. (New) The method of claim 27, wherein said mammal is a dog.

29. (New) In a method of treating an inflammatory disease condition in a mammal responsive to treatment by ovine interferon-tau (IFN_τ), an improvement comprising orally administering a therapeutically-effective amount of bovine IFN_τ through oral ingestion.

30. (New) The method of claim 29, wherein IFN_τ is orally-administered at a dosage of greater than about $1x10^5$ units per day.

31. (New) The method of claim 29, wherein IFN_τ is orally-administered at a dosage of greater than about $1x10^6$ units per day.

32. (New) The method of claim 29, wherein the bovine IFN_τ has an amino acid sequence homology of at least about 80% with an ovine IFN_τ ($OvIFN_\tau$) amino acid sequence.

33. (New) The method of claim 29, wherein said bovine IFN_{τ} has a sequence homology of at least about 80% with an ovine IFN_{τ} sequence represented as SEQ ID NO:2.

A3 cont'd

34. (New) The method of claim 29, wherein said mammal is a human.

35. (New) The method of claim 29, wherein the mammal is a domesticated animal.

36. (New) The method of claim 35, wherein said mammal is a dog.